Mandibular Distraction Osteogenesis in Toddlers with Hemifacial Microsomia: A Five-Year Follow-Up of a Prospective Cohort Trial.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 41086380.
- Also identified by DOI 10.1097/PRS.0000000000012535.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mandibular Distraction Osteogenesis (MDO) is commonly used to treat Hemifacial Microsomia (HFM); however, its long-term efficacy, particularly on maxillary growth, remains unclear. Preliminary studies have suggested that MDO in toddlers may result in better outcomes. This five-year follow-up study evaluated the long-term effects of early MDO on maxillary growth and facial symmetry. A five-year follow-up was conducted in patients who participated in a prospective cohort study. Patients were divided into Group A (surgical age 1-3 years) and Group B (surgical age 4-6 years). The 3D CT data were analyzed. Symmetry was assessed using occlusal plane canting (∠OP) and the symmetry index (affected/unaffected side), and maxillary growth was evaluated using volume and linear measurements. Correlation analysis was performed to explore the relationship between mandibular distraction and maxillary growth. 24 patients completed the 5-year follow-up, with 11 patients in Group A and 13 patients in Group B. Group A showed significant and sustained improvements in facial symmetry and maxillary compensatory growth compared to Group B. The ∠OP in Group A decreased from 4.40° preoperatively to 2.23° postoperatively, with little relapse to 2.51° at five years, while Group B showed less favorable changes. Correlation analysis confirmed a strong relationship between mandibular vertical extension and maxillary growth. Early MDO in toddlers with HFM was demonstrated to be safe and effective, with significant improvements in facial symmetry over a five-year follow-up period. Further studies are warranted to evaluate the longitudinal outcomes of MDO in 1- to 3-year-old HFM patients.